The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 3, 2003, Pages 153-159

  Retter, Avi S ^a   Figg, William D ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen independent prostate cancer; Angiogenesis; Thalidomide; Vascular endothelial growth factor

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALENDRONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; ENDOSTATIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GONADORELIN AGONIST; IRINOTECAN; KETOCONAZOLE; MELPHALAN; MINOCYCLINE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PRINOMASTAT; SEMAXANIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VINBLASTINE;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HYPERTENSION; LIMB DEFECT; METASTASIS; MUSCULOSKELETAL DISEASE; NONHUMAN; PROSTATE CANCER; REVIEW; SIDE EFFECT; TERATOGENICITY; THROMBOSIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 0348225315     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.023     Document Type: Review

References (59)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Figg WD, Feuer JA, Bauer KS. Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy. Cancer Pract 1997; 5:258-263.
3. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992; 10:1754-1761.
4. Pienta KJ, Redman BG, Bandekar R, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50:401-406.
5. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phoshate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15:3156-3163.
6. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-2513.
7. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424.
8. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26:162-173.
9. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28:536-542.
10. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61:253-270.
11. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
12. Brem SS, Jensen HM, Gullino PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978; 41:239-244.
13. Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83:535-555; quiz 555-536.
14. Bostwick DG, Iczkowski KA. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998; 16:118-123.
15. Lissbrant IF, Lissbrant E, Damber JE, et al. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35:437-452.
16. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995; 75:2545-2551.
17. Wakui S, Furusato M, Itoh T, et al. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 1992; 168:257-262.
18. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:401-409.
19. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
20. Ellis LM, Liu W, Fan F, et al. Synopsis of angiogenesis inhibitors in oncology. Oncology (Huntingt) 2002; 16:14-22.
21. Giles FJ. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt) 2002; 16:23-29.
22. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1888-1893.
23. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
24. Yamaoka M, Yamamoto T, Masaki T, et al. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53:4262-4267.
25. Yamaoka M, Yamamoto T, Ikeyama S, et al. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993; 53:5233-5236.
26. Teicher BA. Potentiation of cytotoxic therapies by antioangiogenic agents. In: Teicher BA, ed. Antiangiogenic Agents in Cancer Therapy. Totowa, NJ: Humana Press, 1999:277-316.
27. O'Reilly, MS Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
28. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: ah endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
29. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13:765-782.
30. te Velde EA, Vogten JM, Gebbink MF, et al. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002; 89:1302-1309.
31. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-4160.
32. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-86.
33. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61:3369-3372.
34. Yonekura K, Basaki Y, Fujita H, et al. Inhibition of VEGF/KDR signaling by TSU-68 (SU6668), an oral antiangiogenic agent, can synergistically enhance the antitumor activity of taxol; a new paradigm for breast cancer chemotherapy. Breast Cancer Res Treat 2001; 69:216 (Abstract #29).
35. Figg WD, Arlen P, Gulley J et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001; 28:62-66.
36. Liu Y, Figg WD, Arlen P, et al. A randomized phase II trial of ketoconazole and aledronate vs. ketoconazole in androgen independent prostate cancer (AIPC). Oncology 2003; 17(suppl 4):40-41.
37. Ahmann FR, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2001; 20:174a (Abstract #692).
38. Picus J, Halabi B, Rini N, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22:393 (Abstract #1578).
39. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19:851-856.
40. Hurwitz HI, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer: results of a phase III trial bevacizumab in combination with bolus IFL (irinotecan, 5-flourouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003. (Abstract #3646). Available at: www.asco.org/hurwitz_3646. Accessed June 17, 2003.
41. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001; 28:602-606.
42. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-4085.
43. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55:1827-1834.
44. Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996; 7:339-343.
45. Stearns ME, Wang M Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998; 16:693-702.
46. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
47. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90:704-708.
48. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invas Metastasis 1996; 16:116-131.
49. Shalinsky DR, Brekken J, Zou H, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999; 5:1905-1917.
50. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878:236-270.
51. Reese DM, Fratesi P, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001; 3:65-70.
52. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
53. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
54. Rosen PJ, Amado R, Hecht J, et al. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19:3a (Abstract #5D).
55. Rothenberg ML, Berlin J, Cropp GF, et al. Phase I/II study of SU5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:75a (Abstract #298).
56. SU5416 trials halted. A colorectal cancer trial is the first to shut down. Trials in other indications will follow suit [press release]. Peapack, NJ: Pharmacia, March 2002.
57. Berlin J, Tutsch KD, Hutson P, et al. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 1997; 15:781-789.
58. Ge S, Rempel SA, Divine G, et al. Carboxyamido-triazole induces apoptosis in bovine aortic endothelial and human glioma cells. Clin Cancer Res 2000; 6:1248-1254.
59. Kohn EC, Reed E, Sarosy GA, et al. A phase I trial of carboxyamidotriazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 2001; 7:1600-1609.